The Erosion of Primary Care Purpose: A Critical Examination of the British Government’s Approach

The landscape of primary care in the United Kingdom has experienced transformative shifts in recent years, leading to profound implications for healthcare professionals and patients alike. This post aims to scrutinise the governmental strategies guiding primary care and illuminate the potential erosion of its foundational purpose. Drawing from my experience as an NHS clinician with a commitment to socialist principles, I critically examine these changes and discuss their ramifications for all stakeholders in the healthcare system.
The Importance of Primary Care:Primary care stands as the cornerstone of a robust healthcare system. It is the initial interaction point for individuals seeking medical assistance and offers a spectrum of services from preventive measures and disease management to orchestrating specialised care. Moreover, primary care is pivotal in enhancing public health, curtailing healthcare expenditures, and elevating patient outcomes across the board. According to a study published by the King’s Fund, strong primary care systems are linked with improved health outcomes and lower disparities between different socioeconomic groups.
Government Policies and Their Impact:Recent policies implemented by the British government have sparked widespread apprehensions regarding the trajectory of primary care. The drive towards austerity and an increasing emphasis on privatisation have shifted priorities, potentially diluting the integral role primary care plays within the health ecosystem. Critics argue that such policies divert attention from patient care towards cost-efficiency and market-driven models of health service delivery.
Underfunding and Workforce Shortages:A significant challenge plaguing primary care is chronic underfunding. Reports from the Health Foundation in 2023 indicated a real-terms decrease in primary care funding per capita over the past decade, despite rising patient demands. This underinvestment has strained the existing infrastructure and hampered the development of a resilient workforce. According to the British Medical Association (BMA), there was a deficit of nearly 6,000 GPs in 2024 alone, leading to prolonged wait times, diminished care accessibility, and potential degradation in service quality. These shortages are exacerbated by the high levels of burnout reported among primary care staff, further compromising the sustainability of healthcare services.
Fragmentation and Loss of Continuity:Market-driven reforms have fragmented primary care services, disrupting the continuity of care that is essential for effective medical practice. The proliferation of private clinics and urgent care centers has fragmented patient care pathways, eroding the personalised care model that is fundamental to primary care. Such fragmentation complicates the patient-provider relationship, crucial for a comprehensive healthcare approach. A 2022 report from the NHS Confederation highlighted that fragmentation leads to inefficient utilisation of healthcare resources and could result in poorer health outcomes for patients.
Commercialisation and Profit-Driven Care:An increasing tilt towards commercialisation has introduced a profit-over-patient ethos in primary care settings. The involvement of private entities in primary care under Public-Private Partnership (PPP) models has been criticised for prioritising financial returns over patient care. Reports from the National Audit Office have critiqued several PPPs for not providing value for money, reflecting a misalignment with primary care’s patient-centered ethos. The emphasis on profitability can detract from the quality of care and lead to healthcare practices that do not necessarily align with the best interests of patients.
The Role of Socialism in Reclaiming Primary Care’s Purpose:From a socialist perspective, healthcare is a fundamental right that should be accessible, equitable, and patient-centric. To address the erosion in primary care, there is an urgent need to re-align its operations with these core values. This entails robust government funding, strategic workforce expansions, and a holistic integration of primary care services within the broader health system. Emphasising cooperative practices, patient empowerment, and comprehensive care can ensure that primary care meets the diverse needs of the community.
Conclusion:The gradual erosion of primary care’s purpose in the UK is a pressing issue that requires immediate and thoughtful action. By critically evaluating the government’s approach to primary care, it becomes possible to understand the multifaceted challenges confronting providers and patients. To reclaim the foundational goals of primary care, a collective endeavour rooted in socialist values of equality and comprehensive welfare is indispensable. Together, we can strive towards a health system that not only upholds the principles of socialism but also secures the health and prosperity of every community member.
Reference The King’s Fund - Provides research and analysis on the effectiveness of primary care and its impact on public health. (https://www.kingsfund.org.uk/)
The Health Foundation - Offers insights into funding trends and challenges in the NHS, including issues specific to primary care. (https://www.health.org.uk/)
British Medical Association (BMA) - Publishes annual reports on GP workforce shortages and the state of primary care in the UK. (https://www.bma.org.uk/)
NHS Confederation - Reports on system-wide issues such as the fragmentation of healthcare services and its impacts. (https://www.nhsconfed.org/)
National Audit Office (NAO) - Provides assessments of public spending, including evaluations of Public-Private Partnerships in healthcare. (https://www.nao.org.uk/)
Medscape and BMJ (British Medical Journal) - These medical journals often publish articles and studies related to chronic underfunding, workforce issues, and policy impacts in healthcare systems. (https://www.medscape.com/, https://www.bmj.com/)

The Excessive TV-Watching will cause Dementia, Depression and Parkinson’s Disease

In a digital age where screens often dominate our daily lives, a recent study published in the International Journal of Behavioral Nutrition and Physical Activity offers a thought-provoking insight into the health implications of our viewing habits. This comprehensive analysis, led by Dr. Hanzhang Wu of Tianjin University of Traditional Medicine, China, reveals a concerning correlation between excessive television-watching and an increased risk of dementia, Parkinson's Disease (PD), and depression.

The Study: A Deep Dive into Digital Habits and Health

The research tapped into the UK Biobank, analyzing data from 473,184 individuals aged 39-72 years, followed from 2006 to either a diagnosis of dementia, PD, depression, death, or the study's end. Participants reported their non-work related activities, including exercise, TV-watching, and computer use, alongside undergoing MRI scans to measure brain volume.

The Findings: TV Time and Its Toll

The study's results paint a stark picture: those who indulged in over four hours of TV daily faced a 28% higher risk of dementia, a 35% higher risk of depression, and a 16% greater risk of PD compared to those who watched less than an hour. These figures stand as a cautionary tale against the sedentary lifestyle often associated with excessive TV consumption.

A Silver Lining: Moderate Computer Use

Contrastingly, the study found that moderate computer use (30-60 minutes per day) appeared somewhat protective, lowering the risks for dementia, PD, and depression. This finding challenges the blanket notion that all screen time is detrimental, suggesting that the content and context of digital consumption are key factors.

Exercise: A Vital Substitute

Perhaps most strikingly, replacing just 30 minutes of computer time with structured exercise significantly reduced the risks for dementia and PD. This highlights the immense value of physical activity as a cornerstone of neurological health.

Understanding the Underlying Mechanism

The researchers speculate that the negative impact of prolonged TV-watching might stem from its sedentary nature, which is linked to low-grade inflammation. This inflammation could contribute to neuroinflammation and neurodegeneration, accelerating the onset of diseases like dementia and PD.

Limitations and Considerations

While the study offers valuable insights, it's crucial to note its reliance on self-reported data, which can be subject to recall bias. Additionally, there may be other confounding variables not accounted for in the research.

The Takeaway: Rethinking Our Screen Habits

This study serves as a wake-up call to reassess our daily routines. It suggests that while moderate, purposeful screen use (like computer work) can be part of a healthy lifestyle, excessive, passive screen time (like prolonged TV-watching) might have dire health implications.

 In Practice: Balancing Screen Time with Active Living

For individuals and healthcare professionals alike, the message is clear: balance is key. Integrating regular physical activity into our routines and being mindful of our screen habits could be crucial steps in safeguarding our neurological health.

As we navigate a world increasingly oriented around digital screens, this study underscores the importance of staying active and engaged in a variety of activities. It's not just about cutting screen time; it's about enhancing our overall lifestyle to nurture our physical and mental well-being.

The New Obesity Breakthrough Drugs

There are many holy grails in medicine, with failure after failure, like finding a way to prevent Alzheimer's disease or a non-invasive means for accurately measuring ambulatory blood pressure. But one of the biggest and most daunting has been finding drugs that can tackle obesity — achieving a substantial amount of weight loss without serious side effects. Many attempts to get there now fill a graveyard of failed drugs, such as fen-phen in the 1990s when a single small study of this drug combination in 121 people unleashed millions of prescriptions, some leading to serious heart valve lesions that resulted in withdrawal of the drug in 1995. The drug rimonabant, an endocannabinoid receptor blocker (think of blocking the munchies after marijuana) looked encouraging in randomized trials. However, subsequently, in a trial that I led of nearly 19,000 participants in 42 countries around the world, there was a significant excess of depression, neuropsychiatric side-effects and suicidal ideation which spelled the end of that drug's life.

 

In the United States, where there had not been an anti-obesity drug approved by the FDA since 2014, Wegovy (semaglutide), a once-weekly injection was approved in June 2021. The same drug, at a lower dose, is known as Ozempic (as in O-O-O, Ozempic, the ubiquitous commercial that you undoubtedly hear and see on TV) and had already been approved in January 2020 for improving glucose regulation in diabetes. The next drug on fast track at FDA to be imminently approved is tirzepatide (Mounjaro) following its approval for diabetes in May 2022. It is noteworthy that the discovery of these drugs for weight loss was serendipitous: they were being developed for improving glucose regulation and unexpectedly were found to achieve significant weight reduction.

Both semaglutide and tirzepatide underwent randomized, placebo-controlled trials for obesity, with marked reduction of weight as shown below. Tirzepatide at dose of 10 to 15 mg per week achieved >20% body weight reduction. Semaglutide at a dose of 2.4 mg achieved ~17% reduction. These per cent changes in body weight are 7-9 fold more than seen with placebo (2-3% reduction). Note: these levels of per cent body weight reduction resemble what is typically achieved with the different types of bariatric surgery, such as gastric bypass.

 

Another way to present the data for the 2 trials is shown here, with an edge for tirzepatide at high (10-15 mg) doses, extending to >25% body weight reduction.

 

 

The results with semaglutide were extended to teens in a randomized trial (as shown below), and a similar trial with tirzepatide is in progress.

 

How Do These Drugs Work?

 

These are peptides in the class of incretins, mimicking gut hormones that are secreted after food intake which stimulate insulin secretion.

 

These 2 drugs have in common long half-lives (~ 5 days), which affords once-weekly dosing, but have different mechanisms of action. Semaglutide activates (an agonist) the GLP-1 receptor, while tirzepatide is in a new class of dual agonists: it activates (mimics) both the GLP-1 receptor and GIP receptors (Gastric inhibit polypeptide is also known as glucose-dependent insulinotropic polypeptide.) The potency of activation for tirzepatide is 5-fold more for GIPR than GLP1. As seen below, there are body wide effects that include the brain, liver, pancreas, stomach, intestine, skeletal muscle and fat tissue. While their mode of action is somewhat different, their clinical effects are overlapping, which include enhancing satiety, delaying gastric emptying, increasing insulin and its sensitivity, decreasing glucagon, and, of course, reducing high glucose levels. The overlap extends to side effects of nausea, vomiting, abdominal pain, constipation and diarrhea. Yet only 4 to 6% of participants discontinued the drug in these trials, mostly owing to these GI side effects (and 1-2% in the placebo group discontinued the study drug for the same reasons).

In randomized trials among people with Type 2 diabetes, the drugs achieved HbA1c reduction of at least an absolute 2 percentage points which led to their FDA approvals (For semaglutide in January 2020, and for tirzepatide in May 2022). The edge that tirzepatide has exhibited for weight loss reduction may be related to its dual agonist role, but the enhancement via GIP receptor activation is not fully resolved (as seen below with GIP? designation). The Amgen drug in development (AMG-133) has a marked weight loss effect but inhibits GIP rather than mimics it, clouding our precise understanding of the mechanism.

 

The gut-brain regulation of food intake with the many gut hormones (including leptin, gherlin, PYY, amylin) and targets in the body and brain regions. From Muller et al, Nature Reviews Drug Discovery March 2022. 

Nevertheless, when the two drugs were directly compared in a randomized trial for improving glucose regulation, tirzepatide was superior to semaglutide, as shown below. Of note, both drugs achieved very favorable effects on lipids, reducing triglycerides, LDL and raising HDL cholesterol, along with reduction of blood pressure, an outgrowth of the indirect effect of weight reduction and direct metabolic effects of the drugs.

 

While there has been a concern about other side effects besides the GI ones noted above, review of all the trials to date in these classes of medication do not reinforce a risk of acute pancreatitis. Other rare side effects that have been noted with these drugs include allergic reactions, gallstones (which can occur with a large amount of weight loss), and potential of medullary thyroid cancer (so far only documented in rats, not people), which is why they are contraindicated in people with Type 2 multiple endocrine neoplasia syndrome.

How They Are Given and Practical Considerations

 

For semaglutide, which has FDA approval, the indication is a BMI of 30 kg/m2 or greater than 27 kg/m2 and a weight related medical condition (such as hypertension. hypercholesterolemia or diabetes). To reduce the GI side effects, which mainly occur in the early dose escalation period, semaglutide is given in increasing doses by a prefilled pen by self-injection under the skin (abdomen, thigh or arm) starting at 0.25 mg for a month and gradual increases each month reaching the maximum dose of 2.4 mg at month 5. The FDA label for dosing of tirzepatide has not been provided yet but in the weight loss trial there was a similar dose escalation from 2.5 mg up to 15 mg by month 5. The escalation is essential to reduce the frequent GI side effects, such as seen below in the tirzepatide trial.

 

Semaglutide is very expensive, ~$1500 per month, and not covered by Medicare. There are manufacturer starter coupons from Novo Nordisk, but that is just for the first month. These drugs have to be taken for a year to 18 months to have their full effect and without changes in lifestyle that are durable, it is likely that weight will be regained after stopping them.

What Does This Mean?

 

More than 650 million adults are obese and 13% of the 8 billion world's population (including over 340 million ages 5-18) is obese — that sums us to over 1 billion people. The global obesity epidemic has been relentless, worsening each year, and a driver of "diabesity," the combined dual epidemic. We now have a breakthrough class of drugs that can achieve profound weight loss equivalent to bariatric surgery, along with the side benefits of reducing cardiovascular risk factors (hypertension and hyperlipidemia), improving glucose regulation, reversing fatty liver, and the many detrimental long-term effects of obesity such as osteoarthritis and various cancers. That, in itself, is remarkable. Revolutionary.

 

But the downsides are also obvious. Self-injections, even though they are once a week, are not palatable for many. We have seen far more of these injectables in recent years such as the PCSK-9 inhibitors for hypercholesterolemia or the TNF blockers for autoimmune conditions. That still will not make them a popular item for such an enormous population of potential users.

That brings me to Rybelsus, the oral form of semaglutide, which is approved for glucose regulation improvement but not obesity. It effects for weight loss have been modest compared to Wegovy (5 to 8 pounds for the 7 and 14 mg dose, respectively). But the potential for the very high efficacy of an injectable to be achievable via a pill represents an important path going forward—it could help markedly reduce the cost and uptake.

The problem of discontinuation of the drugs is big, since there are limited data and the likelihood is that the weight will be regained unless there are substantial changes in lifestyle. We know how hard it is to durably achieve such changes, along with the undesirability (and uncertainty with respect to unknown side-effects) of having to take injectable drugs for many years, no less the cost of doing that.

The cost of these drugs will clearly and profoundly exacerbate inequities, since they are eminently affordable by the rich, but the need is extreme among the indigent. We've already seen celebrities take Wegovy for weight loss who are not obese, a window into how these drugs can and will be used without supportive data. As one physician recently observed, "Other than Viagra and Botox, I've seen no other medication so quickly become part of modern culture's social vernacular." Already there are concerns that such use is preventing access to the drugs for those who qualify and need them.

 

There are multiple agents in the class under development which should help increase competition and reduce cost, but they will remain expensive. There is private insurance reimbursement, often with a significant copay, for people who tightly fit the inclusion criteria. Eventual coverage by Medicare will markedly expand their use, and we can expect cost-effectiveness studies to be published showing how much saving there is for the drugs compared with bariatric surgery or not achieving the weight loss. But that doesn't change the cost at the societal level. Even as we've seen with generics, which will ultimately be available, the alleviation of the cost problem isn't what we'd hoped.

 

This is not unlike the recent triumphs of gene therapy, as in $3.5 million for a cure of hemophilia that just got FDA approval, but instead of a rare disease we are talking about the most common medical condition in the world. We finally get across the long sought after (what many would qualify as miraculous) goal line, but the economics collide with the uptake and real benefit.

 

These concerns can't be put aside in the health inequity-laden world we live in, that will unquestionably be exacerbated. However, we cannot miss that this represents one of the most important, biggest medical breakthroughs in history. This may signify the end or marked reduction in the need for bariatric surgery. These drugs will likely become some of the most prescribed of all medications in the upcoming years. While there are many drawbacks, we shouldn't miss such an extraordinary advance in medicine—the first real, potent and safe treatment of obesity.

High Salt Intake Linked to Atherosclerosis Even With Normal Blood Pressure

A large study from Sweden concludes that a high salt intake is an important risk factor for atherosclerosis, even in the absence of hypertension.

The study, including more than 10,000 individuals between the ages of 50 and 64 years from the Swedish Cardiopulmonary bioImage Study, showed a significant link between dietary salt intake and the risk for atherosclerotic lesions in the coronary and carotid arteries, even in participants with normal blood pressure and without known cardiovascular disease.

The finding suggests that salt could be a damaging factor in its own right before the development of hypertension, the authors write. The results were published online March 30 in European Heart Journal Open.

It has been known for a long time that salt is linked to hypertension, but the role that salt plays in atherosclerosis has not been examined, first author, Jonas Wuopio, MD, Karolinska Institutet, Huddinge, and Clinical Research Center, Falun, Uppsala University, both in Sweden, told theheart.org | Medscape Cardiology.

"Hardly anyone looks at changes in the arteries' calcification, the atherosclerotic plaques and the association with salt intake," Wuopio said. "We had this exclusive data from our cohort, so we wanted to use it to close this knowledge gap."
The analysis included 10,788 adults ages 50 to 64 years, (average age, 58 years; 52% women) who underwent a coronary computed tomography angiography (CCTA) scan. The estimated 24-hour sodium excretion was used to measure sodium intake.

CCTA was used to obtain 3D images of the coronary arteries to measure the degree of coronary artery calcium as well as detect stenosis in the coronary arteries. Participants also had an ultrasound of the carotid arteries.

After adjusting for age, sex, and study site (the study was done at Uppsala and Malmö), the researchers found that rising salt consumption was linked with increasing atherosclerosis in a linear fashion in both the coronary and carotid arteries.

Each 1000 mg rise in sodium excretion was associated with a 9% increased occurrence of carotid plaque (odds ratio [OR], 1.09; P < .001; confidence interval [CI], 1.06 - 1.12), a higher coronary artery calcium score (OR, 1.16; P < .001; CI, 1.12 - 1.19), and a 17% increased occurrence of coronary artery stenosis (OR, 1.17; P < .001; CI, 1.13 - 1.20).

The association was abolished, though, after adjusting for blood pressure, they note. Their "interpretation is that the increase in blood pressure from sodium intake, even below the level that currently defines arterial hypertension, is an important factor that mediates the interplay between salt intake and the atherosclerotic process," they write. "As we observed an association in individuals with normal blood pressure, one possible explanation for these findings is that the detrimental pathological processes begin already prior to the development of hypertension," they note, although they caution that no causal relationships can be gleaned from this cross-sectional study. 

They also reported no sign of a "J-curve"; participants with the lowest levels of sodium excretion had the lowest occurrence of both coronary and carotid atherosclerosis, which contradicts findings in some studies that found very low sodium linked to increased cardiovascular disease–related events.

"There have been some controversies among researchers regarding very low intake, where some say very low salt intake can increase the risk of cardiovascular disease, but we could not find this in this study," Wuopio said.

"Our study is confirming that excess salt is not a good thing, but the fact that it is linked to atherosclerosis, even in the absence of hypertension, was a bit of a surprise," he said.

"I will be telling my patients to follow the advice given by the World Health Organization and other medical societies, to limit your intake of salt to approximately 1 teaspoon, even if your blood pressure is normal."

Maciej Banach, MD, Medical University of Lodz, and Stanislaw Surma, MD, Faculty of Medical Sciences in Katowice, both in Poland, write that excessive dietary salt intake is a well-documented cardiovascular risk factor, and that the association is explained in most studies by increased blood pressure.

"We should look more extensively on the role of dietary salt, as it affects many pathological mechanisms, by which, especially with the coexistence of other risk factors, atherosclerosis may progress very fast," they write."The results of the study shed new light on the direct relationship between excessive dietary salt intake and the risk of ASCVD [atherosclerotic cardiovascular disease], indicating that salt intake might be a risk factor for atherosclerosis even prior to the development of hypertension," they conclude.

Parkinson Disease

Parkinson disease (PD) is one of the most common neurologic disorders, affecting approximately 1% of individuals older than 60 years and causing progressive disability that can be slowed, but not halted, by treatment. The 2 major neuropathologic findings in Parkinson disease are loss of pigmented dopaminergic neurons of the substantia nigra pars compacta and the presence of Lewy bodies and Lewy neurites.

Signs and symptoms

Initial clinical symptoms of Parkinson disease include the following:

• Tremor
  
• Subtle decrease in dexterity
  
• Decreased arm swing on the first-involved side
  
• Soft voice
  
• Decreased facial expression
  
• Sleep disturbances
  
• Rapid eye movement (REM) behavior disorder (RBD; a loss of normal atonia during REM sleep)
  
• Decreased sense of smell
  
• Symptoms of autonomic dysfunction (eg, constipation, sweating abnormalities, sexual dysfunction, seborrheic dermatitis)
  
• A general feeling of weakness, malaise, or lassitude
  
• Depression or anhedonia
  
• Slowness in thinkin

Onset of motor signs include the following:

• Typically asymmetric
  
• The most common initial finding is a resting tremor in an upper extremity
  
• Over time, patients experience progressive bradykinesia, rigidity, and gait difficulty
  
• Axial posture becomes progressively flexed and strides become shorter
  
• Postural instability (balance impairment) is a late phenomenon

Nonmotor symptoms

Nonmotor symptoms are common in early Parkinson disease. Recognition of the combination of nonmotor and motor symptoms can promote early diagnosis and thus early intervention, which often results in a better quality of life.

Diagnosis

Parkinson disease is a clinical diagnosis. No laboratory biomarkers exist for the condition, and findings on routine magnetic resonance imaging and computed tomography scans are unremarkable.

Clinical diagnosis requires the presence of 2 of 3 cardinal signs:

• Resting tremor
  
• Rigidity
  
• Bradykinesia
  

Management

The goal of medical management of Parkinson disease is to provide control of signs and symptoms for as long as possible while minimizing adverse effects.

Symptomatic drug therapy

• Usually provides good control of motor signs of Parkinson disease for 4-6 years
  
• Levodopa/carbidopa: The gold standard of symptomatic treatment
  
• Monoamine oxidase (MAO)–B inhibitors: Can be considered for initial treatment of early disease
  
• Other dopamine agonists (eg, ropinirole, pramipexole): Monotherapy in early disease and adjunctive therapy in moderate to advanced disease
  
• Anticholinergic agents (eg, trihexyphenidyl, benztropine): Second-line drugs for tremor only
  

Treatment for nonmotor symptoms

• Sildenafil citrate (Viagra): For erectile dysfunction
  
• Polyethylene glycol: For constipation
  
• Modafinil: For excessive daytime somnolence
  
• Methylphenidate: For fatigue (potential for abuse and addiction)
  

Deep brain stimulation

• Surgical procedure of choice for Parkinson disease
  
• Does not involve destruction of brain tissue
  
• Reversible
  
• Can be adjusted as the disease progresses or adverse events occur
  
• Bilateral procedures can be performed without a significant increase in adverse events
  

Prognosis

Before the introduction of levodopa, Parkinson disease caused severe disability or death in 25% of patients within 5 years of onset, 65% within 10 years, and 89% within 15 years. The mortality rate from Parkinson disease was 3 times that of the general population matched for age, sex, and racial origin. With the introduction of levodopa, the mortality rate dropped approximately 50%, and longevity was extended by many years. This is thought to be due to the symptomatic effects of levodopa, as no clear evidence suggests that levodopa stems the progressive nature of the disease.

The American Academy of Neurology notes that the following clinical features may help predict the rate of progression of Parkinson disease :
Older age at onset and initial rigidity/hypokinesia can be used to predict (1) a more rapid rate of motor progression in those with newly diagnosed Parkinson disease and (2) earlier development of cognitive decline and dementia; however, initially presenting with tremor may predict a more benign disease course and longer therapeutic benefit from levodopa
A faster rate of motor progression may also be predicted if the patient is male, has associated comorbidities, and has postural instability/gait difficulty (PIGD)
Older age at onset, dementia, and decreased responsiveness to dopaminergic therapy may predict earlier nursing home placement and decreased survival
Patient Education

Patients with Parkinson disease should be encouraged to participate in decision making regarding their condition. In addition, individuals and their caregivers should be provided with information that is appropriate for their disease state and expected or ongoing challenges. Psychosocial support and concerns should be addressed and/or referred to a social worker or psychologist as needed.

Prevention of falls should be discussed. The UK National Institute for Health and Clinical Excellence has several guidance documents including those for patients and caregivers.

Other issues that commonly need to be addressed at appropriate times in the disease course include cognitive decline, personality changes, depression, dysphagia, sleepiness and fatigue, and impulse control disorders. Additional information is also often needed for financial planning, insurance issues, disability application, and placement (assisted living facility, nursing home).